Opening Asia for Russia

Persons over 60 years of age may be allowed to test the vaccine "Kovivak"

25.08.2021 129 просмотров

The Chumakov Center expects in September the admission of persons over 60 years of age to the tests of Kovivak.

Center them. Chumakova expects to receive permission to conduct a third stage clinical trial of the Kovivac vaccine in people over 60 years of age in September. Aidar Ishmukhametov, Director General of the Center, Corresponding Member of the Russian Academy of Sciences, announced this on air on the Rossiya-24 TV channel.

“We are allowed the third post-vaccination stage. We have not received permission for 60+ yet, we expect it in two weeks, tentatively in September,” he said.

Aidar Ishmukhametov placebo. “The process of submitting documents will be done in stages. After that, we will apply for comorbidities, autoimmune, COPD (chronic obstructive pulmonary disease - TASS note) and oncological diseases. And here is our program for the next two months. And now the first part, this is the first thousand patients in whom we are looking at immunological efficacy,” he said.

Previously, the Chumakov Center requested permission from the Ministry of Health of the Russian Federation to use the Kovivak vaccine developed by it on people over 60 years old and those suffering from chronic diseases.

On February 19, the Ministry of Health of Russia registered the inactivated whole-virion vaccine Kovivak, developed at the Federal State Budgetary Scientific Institution “Federal Research Center for Research and Development of Immunobiological Preparations named after I.I. M.P. Chumakov RAS” (Chumakov Center). Whole-virion vaccines use either artificially weakened viruses that are not capable of causing disease, or viruses that have already been killed (inactivated).

Новости партнёров